BG110386A - USE OF ANTAGONISTS OF CENTRAL RECEPTORS OF CANNABINOIDS FOR THE RECEIPT OF MEDICINAL PRODUCTS TO FACILITATE THE STOPPING OF TOBACCO CONSUMPTION - Google Patents

USE OF ANTAGONISTS OF CENTRAL RECEPTORS OF CANNABINOIDS FOR THE RECEIPT OF MEDICINAL PRODUCTS TO FACILITATE THE STOPPING OF TOBACCO CONSUMPTION

Info

Publication number
BG110386A
BG110386A BG110386A BG11038601A BG110386A BG 110386 A BG110386 A BG 110386A BG 110386 A BG110386 A BG 110386A BG 11038601 A BG11038601 A BG 11038601A BG 110386 A BG110386 A BG 110386A
Authority
BG
Bulgaria
Prior art keywords
antagonist
central
medicines used
tobacco consumption
facilitate stopping
Prior art date
Application number
BG110386A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jean BLANCHARD
Francois Menard
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of BG110386A publication Critical patent/BG110386A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG110386A 2000-02-09 2001-02-07 USE OF ANTAGONISTS OF CENTRAL RECEPTORS OF CANNABINOIDS FOR THE RECEIPT OF MEDICINAL PRODUCTS TO FACILITATE THE STOPPING OF TOBACCO CONSUMPTION BG110386A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
BG110386A true BG110386A (en) 2009-09-30

Family

ID=8846875

Family Applications (2)

Application Number Title Priority Date Filing Date
BG110386A BG110386A (en) 2000-02-09 2001-02-07 USE OF ANTAGONISTS OF CENTRAL RECEPTORS OF CANNABINOIDS FOR THE RECEIPT OF MEDICINAL PRODUCTS TO FACILITATE THE STOPPING OF TOBACCO CONSUMPTION
BG106946A BG65856B1 (bg) 2000-02-09 2002-07-23 Използване на антагонисти на централни канабиноидни рецептори за получаване на лекарствени средства за улесняване спирането на консумацията на тютюн

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG106946A BG65856B1 (bg) 2000-02-09 2002-07-23 Използване на антагонисти на централни канабиноидни рецептори за получаване на лекарствени средства за улесняване спирането на консумацията на тютюн

Country Status (32)

Country Link
US (2) US6930122B2 (enExample)
EP (1) EP1257275B1 (enExample)
JP (2) JP2003522145A (enExample)
CN (1) CN1250220C (enExample)
AR (1) AR028505A1 (enExample)
AT (1) ATE292467T1 (enExample)
AU (1) AU781827B2 (enExample)
BG (2) BG110386A (enExample)
BR (1) BR0108126A (enExample)
CA (1) CA2397262C (enExample)
CZ (1) CZ296685B6 (enExample)
DE (1) DE60109903T2 (enExample)
DK (1) DK1257275T3 (enExample)
EE (1) EE04836B1 (enExample)
ES (1) ES2240416T3 (enExample)
FR (1) FR2804604B1 (enExample)
HU (1) HU225328B1 (enExample)
IL (1) IL150710A0 (enExample)
IS (1) IS6450A (enExample)
MX (1) MXPA02007766A (enExample)
NO (1) NO324521B1 (enExample)
NZ (1) NZ519924A (enExample)
PL (1) PL201685B1 (enExample)
PT (1) PT1257275E (enExample)
RS (1) RS50404B (enExample)
RU (1) RU2257207C2 (enExample)
SI (1) SI1257275T1 (enExample)
SK (1) SK284952B6 (enExample)
TW (1) TWI243677B (enExample)
UA (1) UA72783C2 (enExample)
WO (1) WO2001058450A2 (enExample)
ZA (1) ZA200205317B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
CN1568432A (zh) 2001-08-13 2005-01-19 霍尼韦尔国际公司 使用沟槽为晶片承载的半导体器件提供电流控制
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7390835B2 (en) * 2003-10-30 2008-06-24 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
WO2007084450A2 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
WO2009005646A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
NO20023765D0 (no) 2002-08-08
FR2804604A1 (fr) 2001-08-10
UA72783C2 (en) 2005-04-15
FR2804604B1 (fr) 2005-05-27
HU225328B1 (en) 2006-09-28
CZ296685B6 (cs) 2006-05-17
EE04836B1 (et) 2007-06-15
HUP0300237A3 (en) 2003-09-29
ATE292467T1 (de) 2005-04-15
MXPA02007766A (es) 2002-10-11
SK11292002A3 (sk) 2003-02-04
US6930122B2 (en) 2005-08-16
WO2001058450A3 (fr) 2002-04-25
HUP0300237A2 (hu) 2003-07-28
SK284952B6 (sk) 2006-03-02
CZ20022698A3 (cs) 2002-11-13
CN1250220C (zh) 2006-04-12
US20030087933A1 (en) 2003-05-08
PL201685B1 (pl) 2009-04-30
DE60109903T2 (de) 2006-02-09
BR0108126A (pt) 2003-01-28
US20050187253A1 (en) 2005-08-25
WO2001058450A2 (fr) 2001-08-16
BG65856B1 (bg) 2010-03-31
RU2002118309A (ru) 2004-02-20
DK1257275T3 (da) 2005-08-08
TWI243677B (en) 2005-11-21
RS50404B (sr) 2009-12-31
AR028505A1 (es) 2003-05-14
NO324521B1 (no) 2007-11-12
JP2010018622A (ja) 2010-01-28
AU781827B2 (en) 2005-06-16
ZA200205317B (en) 2003-09-04
EP1257275A2 (fr) 2002-11-20
PL358221A1 (en) 2004-08-09
IL150710A0 (en) 2003-02-12
NO20023765L (no) 2002-10-09
PT1257275E (pt) 2005-07-29
ES2240416T3 (es) 2005-10-16
EP1257275B1 (fr) 2005-04-06
CA2397262A1 (en) 2001-08-16
DE60109903D1 (de) 2005-05-12
SI1257275T1 (en) 2005-10-31
YU59002A (sh) 2005-07-19
HK1051140A1 (en) 2003-07-25
CN1406128A (zh) 2003-03-26
IS6450A (is) 2002-06-28
EE200200439A (et) 2003-12-15
RU2257207C2 (ru) 2005-07-27
JP2003522145A (ja) 2003-07-22
AU3562001A (en) 2001-08-20
NZ519924A (en) 2005-01-28
BG106946A (bg) 2003-05-30
CA2397262C (en) 2007-09-11

Similar Documents

Publication Publication Date Title
PL358221A1 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
UA49056C2 (uk) Фармацевтична композиція для перорального застосування аміду n-піперидин-5-(4-хлорфеніл)-1-(2,4-дихлорфеніл)-4-метилпіразол-3-карбонової кислоти, його солей і сольватів та спосіб її отримання
UA66900C2 (uk) Похідні піразолкарбонової кислоти, спосіб їх виготовлення, фармацевтична композиція, що їх містить
MY136969A (en) Mpeg table structure
RU94042232A (ru) Замещенный n-пиперидино-3-пиразолкарбоксамид, способ его получения и фармкомпозиция на их основе
MXPA03002291A (es) Compuestos de pirazol utiles como inhibidores de proteina cinasa.
MXPA03005607A (es) Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
AU2002331766A1 (en) Novel pyrazole analogs acting on cannabinoid receptors
ATE480539T1 (de) Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
HUP0300867A3 (en) Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof and pharmaceutical compositions containing the compounds
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
CY1112078T1 (el) Χρηση των ανταγωνιστων του cb1 υποδοχεα για την παρασκευη ενος σκευασματος που θα χρησιμοποιηθει για τη θεραπεια των ηπατικων νοσων
WO2001085092A3 (fr) Antagoniste des recepteurs aux cannabinoides cb-1 antidiarrheique
MXPA02012400A (es) Heterociclos hetaril-substituidos.
DK1387837T3 (da) Hidtil ukendte azol- eller triazolderivater, fremgangsmåden til deres fremstilling og deres anvendelse som antimykotiske lægemidler
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
WO2001056590A3 (de) Verwendung von proteinkinase-inhibitor-alpha
HUP0004154A3 (en) Process for the preparation of 1,5-disubstituted-3-amino-1,2,4-triazole derivatives
GB0018662D0 (en) Novel process for the preparation of pyrazoles